Founder & CEO
Pierrette Hebga Meinrad
Policy and innovation background, with lived experience of neurological care and a focus on building more representative evidence systems.
LinkedInOur story
Mylenium started
with a question.
What would neurological care look like if the months between appointments were visible too?
Why Mylenium
A clearer picture of change.
Mylenium grew from years of watching neurological care work from fragments.
Founder Pierrette Hebga Meinrad spent years supporting her mother through tremor and repeated treatment changes. The experience exposed a simple problem: much of what determines whether treatment is working happens outside the consultation room.
Mylenium is being built to capture that missing longitudinal picture and make it more useful for people, care teams and research.
Our thesis
Better neurological care depends on better longitudinal information.
Symptoms change. Treatments change. Daily life changes. Understanding those relationships over time can create better evidence for patients, care teams and researchers.
01Capture
02Structure
03Understand
04Apply
Company progress
From question to evidence
£25k non-dilutive funding secured
First longitudinal pilot completed — 127 participants · 2,600+ check-ins
Clinical, regulatory and market-access work underway
Pre-seed round opens
Team
Built across lived experience, technology and strategy.
Engineer
Nizar Bikti
Full-stack and machine-learning capability supporting product and technical development.
LinkedIn
Strategy & Growth Advisor
Gunjan Arora
Strategy, operations and growth experience across complex organisations and scaling environments.
LinkedInOur structure is designed to grow with future clinical, regulatory, research and engineering expertise.
There is more to the conversation.
We are speaking with investors, clinicians, researchers, patient organisations and potential partners.
Pre-seed round opening October 2026